- Home
- FULC vs LBRX Comparison
FULC vs LBRX Comparison
Compare FULC & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FULC | LBRX |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 707.9M | 602.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FULC | LBRX |
|---|---|---|
| Price | $10.71 | $24.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 3 |
| Target Price | $16.38 | ★ $49.00 |
| AVG Volume (30 Days) | ★ 592.5K | 180.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.32 | $13.36 |
| 52 Week High | $15.74 | $24.95 |
Technical Indicators
Market Signals| Indicator | FULC | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 52.04 | 58.48 |
| Support Level | $10.04 | $23.52 |
| Resistance Level | $11.17 | $24.84 |
| Average True Range (ATR) | 0.65 | 1.58 |
| MACD | 0.07 | 0.08 |
| Stochastic Oscillator | 75.28 | 81.96 |
Price Performance
Historical ComparisonAbout FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
About LBRX LB Pharmaceuticals Inc
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.